{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:27:20Z","timestamp":1792902440311,"version":"4.5.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2) is highly expressed in various solid tumors, and its abnormal activation is closely associated with poor tumor prognosis, establishing it as a prominent target in contemporary research. The successful clinical treatment of multiple HER2-positive tumors with HER2 antibodies has prompted researchers to design chimeric antigen receptor T (CAR-T) cells targeting HER2 for solid tumor immunotherapy. To date, the development of CAR structures has progressed to the fifth generation, with most HER2-CAR-T cell structures being modified based on the second-generation CAR architecture. This review will delineate the structure and cytotoxic mechanism of HER2-CAR-T cells, elucidate the difficulties and optimization strategies for HER2-CAR-T cell therapy, and summarize recent clinical applications and advancements.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1514994","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:23:25Z","timestamp":1747805005000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Liaoliao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.12.014","article-title":"Recent advances in HER2-targeted delivery for cancer therapy","volume":"26","author":"Dhritlahre","year":"2021","journal-title":"Drug Discov Today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.03.010","article-title":"Prevalence and role of HER2 mutations in cancer","volume":"199","author":"Cocco","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.141962","article-title":"Arsenic-induced HER2 promotes proliferation, migration and angiogenesis of bladder epithelial cells via activation of multiple signaling pathways in vitro and in vivo","volume":"753","author":"Zhou","year":"2021","journal-title":"Sci Total Environ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-022-01876-9","article-title":"The clinical significance of HER2 expression in DCIS","volume":"40","author":"Akrida","year":"2022","journal-title":"Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.11.030","article-title":"Effects of HER2 on the invasion and migration of gastric cancer","volume":"11","author":"Luo","year":"2019","journal-title":"Am J Transl Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis","year":"2008","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/jcm12103391","article-title":"History and future of HER2-targeted therapy for advanced gastric cancer","volume":"12","author":"Ariga","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung","year":"2021","journal-title":"Future Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201804_14752","article-title":"Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer","volume":"22","author":"Nicolazzi","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00095-1","article-title":"Landscape of cancer cell therapies: trends and real-world data","volume":"21","author":"Saez-Ibanez","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/cells12131770","article-title":"Chimeric antigen receptor T cells in glioblastoma-current concepts and promising future","volume":"12","author":"Kringel","year":"2023","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154888","article-title":"Translational research of new developments in targeted therapy of colorectal cancer","volume":"252","author":"Yang","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S368138","article-title":"From anti-HER-2 to anti-HER-2-CAR-T cells: an evolutionary immunotherapy approach for gastric cancer","volume":"15","author":"Sun","year":"2022","journal-title":"J Inflammation Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.11.6577","article-title":"Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors","volume":"151","author":"Stancovski","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","article-title":"Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies","volume":"484","author":"Szoor","year":"2020","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031039","article-title":"A small number of HER2 redirected CAR T cells significantly improves immune response of adoptively transferred mouse lymphocytes against human breast cancer xenografts","volume":"21","author":"T\u00f3th","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume":"9","author":"Song","year":"2018","journal-title":"Protein Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12967-021-03132-6","article-title":"Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers","volume":"19","author":"Yang","year":"2021","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0565","article-title":"Immunogenetic metabolomics reveals key enzymes that modulate CAR T-cell metabolism and function","volume":"11","author":"Renauer","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci - PNAS"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aap9777","article-title":"An immunoproteomic approach to characterize the CAR interactome and signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Sci Signal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00275-6","article-title":"HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo","volume":"25","author":"Li","year":"2024","journal-title":"Genes Immun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR T cells","volume":"24","author":"Velasco","year":"2023","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c01177","article-title":"Expression-dependent tumor pretargeting via engineered avidity","volume":"22","author":"Harthorn","year":"2025","journal-title":"Mol Pharm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"Gomez-Melero","year":"2025","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007426","article-title":"HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity","volume":"11","author":"Bassan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/procel\/pwae034","article-title":"A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell Malignancies","volume":"16","author":"Zhao","year":"2025","journal-title":"Protein Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e970027","DOI":"10.4161\/21624011.2014.970027","article-title":"Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment","volume":"3","author":"Beatty","year":"2014","journal-title":"Oncoimmunology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/vaccines4040046","article-title":"Tumor microenvironment metabolism: A new checkpoint for anti-tumor immunity","volume":"4","author":"Scharping","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1757360","DOI":"10.1080\/2162402X.2020.1757360","article-title":"Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model","volume":"9","author":"Murty","year":"2020","journal-title":"Oncoimmunology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e2102624","DOI":"10.1002\/smll.202102624","article-title":"Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T cells for combination therapy","volume":"17","author":"Zhu","year":"2021","journal-title":"Small"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.278","article-title":"Combining oncolytic viruses with chimeric antigen receptor T cell therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum Gene Ther"},{"key":"B70","doi-asserted-by":"publisher","first-page":"15014","DOI":"10.1038\/mto.2015.14","article-title":"Chimeric antigen receptor-engineered T cells as oncolytic virus carriers","volume":"2","author":"VanSeggelen","year":"2015","journal-title":"Mol Ther Oncolyt"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with biTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01143","article-title":"The third generation anti-HER2 chimeric antigen receptor mouse T cells alone or together with anti-PD1 antibody inhibits the growth of mouse breast tumor cells expressing HER2 in vitro and in immune competent mice","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus\u2013expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells","volume":"39","author":"Masoumi","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.07.003","article-title":"CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells","volume":"22","author":"Li","year":"2021","journal-title":"Mol Ther Oncolyt"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.035","article-title":"A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells","volume":"187","author":"Tieu","year":"2024","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","article-title":"GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency","volume":"15","author":"Guerrero","year":"2024","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.05.017","article-title":"BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism","volume":"32","author":"Yang","year":"2024","journal-title":"Mol Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"139r","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13642","article-title":"T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it","volume":"169","author":"Yin","year":"2023","journal-title":"Immunology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor T-cell efficacy in solid tumors","volume":"26","author":"Fuca","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e65291","DOI":"10.7759\/cureus.65291","article-title":"Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence","volume":"16","author":"Ghorai","year":"2024","journal-title":"Cureus"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence","volume":"13","author":"Lopez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178558","article-title":"IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells","volume":"135","author":"Fu","year":"2024","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003046","article-title":"Targeting metabolism to improve CAR-T cells therapeutic efficacy","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-020-00238-9","article-title":"Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing","volume":"8","author":"Liao","year":"2020","journal-title":"Biomark Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02054","article-title":"Optimization of CAR-T cell-based therapies using small-molecule-based safety switches","volume":"64","author":"Zheng","year":"2021","journal-title":"J Med Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/ijms18091797","article-title":"Human CD3+ T-cells with the anti-ERBB2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in ERBB2 overexpressing breast cancer cells","volume":"18","author":"Munisvaradass","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01176.x","article-title":"HER2 overexpression correlates with survival after curative resection of pancreatic cancer","volume":"100","author":"Komoto","year":"2009","journal-title":"Cancer Sci"},{"key":"B104","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-Cells Targeting the Integrin alphavbeta6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/cancers12010054","article-title":"DCLK1 monoclonal antibody-based CAR-T cells as a novel treatment strategy against human colorectal cancers","volume":"12","author":"Sureban","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade6790","article-title":"Ultralow-dose binary oncolytic\/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"B111","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/mab.2023.0033","article-title":"Establishment of a novel cancer-specific anti-HER2 monoclonal antibody H(2)Mab-250\/H(2)CasMab-2 for breast cancers","volume":"43","author":"Kaneko","year":"2024","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"B112","doi-asserted-by":"publisher","first-page":"A307","DOI":"10.1136\/jitc-2023-SITC2023.0268","article-title":"268 Development of FT825\/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression","volume":"11","author":"Hosking","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13287-022-02719-0","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress","volume":"13","author":"Budi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol BioMed"},{"key":"B116","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B118","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.3390\/ijms24076843","article-title":"Engineering a HER2-CAR-NK cell secreting soluble programmed cell death protein with superior antitumor efficacy","volume":"24","author":"Xia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155920","article-title":"Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud","volume":"156","author":"Muthuvel","year":"2022","journal-title":"Cytokine"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114361","article-title":"Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India","volume":"201","author":"SK","year":"2024","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1514994\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:23:26Z","timestamp":1747805006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1514994\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2025.1514994"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1514994","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1514994"}}